Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants

[1]  A. Hansen,et al.  Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. , 2008, Blood.

[2]  Je-Jung Lee,et al.  Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV‐seropositive recipients and donors , 2008, American journal of hematology.

[3]  R. Vij,et al.  Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Blood.

[4]  G. Cook,et al.  Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.

[5]  D. Lilleri,et al.  Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection , 2008, Haematologica.

[6]  Peter Shaw,et al.  Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  E. Claas,et al.  Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning , 2007, Bone Marrow Transplantation.

[8]  E. Thiel,et al.  Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.

[9]  C. Pannuti,et al.  Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anti-cytomegalovirus immune response and risk for its reactivation. , 2006, Clinical immunology.

[10]  T. Zimmerman,et al.  Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning , 2006, Bone Marrow Transplantation.

[11]  R. Krance,et al.  Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab , 2005, Bone Marrow Transplantation.

[12]  H. Nieuwenhuis,et al.  Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation , 2004, Transplant infectious disease : an official journal of the Transplantation Society.

[13]  P. Moss,et al.  CD8(+) T-cell immunity to cytomegalovirus. , 2004, Human immunology.

[14]  M. N. Kim,et al.  The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell Transplantation Compared with Conventional Bone Marrow Transplantation , 2004, Journal of Korean medical science.

[15]  D. Olive,et al.  Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen , 2004, Bone Marrow Transplantation.

[16]  S. Riddell,et al.  Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. , 2003, Blood.

[17]  W. Siegert,et al.  Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia , 2003, Bone Marrow Transplantation.

[18]  M. Maris,et al.  Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. , 2003, Experimental hematology.

[19]  D. Cirillo,et al.  Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation , 2003, Transplant infectious disease : an official journal of the Transplantation Society.

[20]  M. Haun,et al.  Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation , 2003, Annals of Hematology.

[21]  S. Rowland-Jones,et al.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.

[22]  S. Solomon,et al.  High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[23]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[24]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[25]  A. Zander,et al.  Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin , 2001, British journal of haematology.

[26]  T. Shiohara,et al.  Current understanding of cytomegalovirus infection in immunocompetent individuals. , 2000, Journal of dermatological science.

[27]  V. Kuenen-Boumeester,et al.  Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.

[28]  H. Balfour,et al.  Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. , 1986, Blood.

[29]  S. Mackinnon,et al.  Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. , 2008, Blood cells, molecules & diseases.

[30]  J. Antin.  Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. , 2007, Hematology. American Society of Hematology. Education Program.

[31]  P. Ljungman,et al.  Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. , 2006, Haematologica.

[32]  M. Boccadoro,et al.  Corticosteroids can reverse severe imatinib-induced hepatotoxicity. , 2006, Haematologica.

[33]  藤崎譲士,et al.  Reduced Intensity Stem Cell Transplantationにおけるシクロスポリンの至適投与量 , 2004 .

[34]  S. Mineishi,et al.  Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin , 2002, Bone Marrow Transplantation.